← Human Trials & Peer-Reviewed Studies
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
Plain-language guide to NCT07335796: phase 2 interventional trial of Degarelix, 7 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07335796
- Phase
- phase 2
- Status
- active, not recruiting
- Start
- 2026-01-09
- Completion (planned or actual)
- 2030-01-09
- Participants
- 7 (actual)
- Design
- na, open label (everyone knows who gets what), treatment
- Conditions studied
- Prostate Cancer
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
In this phase 2 trial, researchers set out to test Degarelix.
It had 1 arm (groups): one (experimental).
The registry classes the interventions as drug.
Who Took Part
The registry lists 7 actual participants took part.
It was open to people of any sex aged from 18 years with no upper age limit.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: PSA ≥ 20ng/ml or. Gleason ≥8 or. Clinical stage ≥cT3a. Candidate for RP as determined by treating physician. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
The full record lists 10 inclusion and 18 exclusion criteria; among the exclusions: on adt (gnrh agonists or antagonists) for \> 4 weeks at time of consent; any patient who cannot swallow oral medications or have gastrointestinal disorders in the opinion of the investigator are likely to interfere with absorption; participant would be excluded if the qtcf interval cannot be determined on the screening ecg (eg, unreadable or not interpretable).
How the Study Was Run
It was run as a single-group and open-label study.
Nothing was hidden in this open-label Degarelix study: the participants and staff both knew the treatment.
Everyone received the same intervention, so there was no separate comparison group inside the trial.
It started in 2026-01-09 with completion listed for 2030-01-09.
It ran at 6 sites in United States (6).
Its stated primary purpose is treatment.
What Was Measured
Researchers chose this as the main measure: Frequency of pathologic complete response/pCR (time frame: 42 months).
What This Means in Plain Language
Put simply, this is a phase 2 trial of Degarelix in 7 people.
Its size is small, so on its own it can only give an early look.
Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Degarelix compound page, all human trials.
Our Notes on the Compound
Degarelix: A GnRH antagonist injection (Firmagon) for advanced prostate cancer that lowers testosterone within days without the initial surge seen with agonists.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.